Alkermes plc (ALKS) Financials

ALKS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 2.1 billion 933.5 million
2023-09-30 2.3 billion 923.6 million
2023-06-30 2.2 billion 906.7 million
2023-03-31 1.9 billion 917.2 million

ALKS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 90.2 million 25.8 million
2023-09-30 85.3 million 23.9 million
2023-06-30 206.0 million 28.5 million
2023-03-31 -28.2 million 22.6 million

ALKS Net Income

No data available :(

ALKS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 813.4 million - 81.5 million
2023-09-30 995.6 million - 93.6 million
2023-06-30 907.2 million - 97.5 million
2023-03-31 692.5 million 289.6 million 101.4 million

ALKS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 170.1 million
2023-09-30 171.9 million
2023-06-30 171.6 million
2023-03-31 165.1 million

ALKS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 17.0 million 73.9 million 24.3 million 116.3 million
2023-09-30 14.5 million 97.1 million 54.6 million 114.8 million
2023-06-30 9.7 million 7000 205.3 million -
2023-03-31 6.9 million 93.6 million 56.0 million 118.5 million

ALKS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 377.5 million 79.1 million
2023-09-30 380.9 million 61.5 million
2023-06-30 617.4 million 164.0 million
2023-03-31 287.6 million 58.2 million

ALKS

Price: $24.01

52 week price:
22.01
33.71

Payout Ratio Range:
-172.23%
-77.67%

Earnings Per Share: 3.06 USD

P/E Ratio: 22.03

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 283127

Ebitda: 39.2 million

Market Capitalization: 4.4 billion

Links: